Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk Factors for Suicide Among Professional Athletes.

Journal of psychiatric practice·2024

Same author

Comparison of Pain With Ultrasound-Guided Intra-Articular Hip Injections With and Without Prior Subcutaneous Local Anesthesia.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine·2024

Same author

Rapid nitrogen loss from ectomycorrhizal pine germinants signaled by their fungal symbiont.

Mycorrhiza·2020

Same author

High-Dimensional Analysis of Postsplenectomy Peripheral Immune Cell Changes.

ImmunoHorizons·2020

Same author

11-Ketotestosterone Is the Dominant Circulating Bioactive Androgen During Normal and Premature Adrenarche.

The Journal of clinical endocrinology and metabolism·2018

Same author

Age-dependent Increases in Adrenal Cytochrome b5 and Serum 5-Androstenediol-3-sulfate.

The Journal of clinical endocrinology and metabolism·2016

Search research articles

Related Experiment Video

Updated: May 30, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Pharmacotherapy for fibromyalgia.

Howard S Smith¹, Donna Bracken, Joshua M Smith

¹Department of Anesthesiology, Albany Medical College Albany, NY, USA.

Frontiers in Pharmacology

|July 21, 2011

Summary

This summary is machine-generated.

Fibromyalgia (FM) is a chronic pain disorder affecting 2-4% of the population. This review focuses on pharmacologic treatments for FM symptoms, including FDA-approved and non-approved agents.

Keywords:

duloxetine efficacy fibromyalgia milnacipran pain pharmacotherapy pregabalin

More Related Videos

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Related Experiment Videos

Last Updated: May 30, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Area of Science:

Rheumatology
Pain Management
Pharmacology

Background:

Fibromyalgia (FM) is a chronic condition affecting 2-4% of the population, causing widespread pain, fatigue, insomnia, and cognitive difficulties.
FM significantly impairs physical functioning, emotional health, social life, and overall quality of life.

Purpose of the Study:

To review current understanding of fibromyalgia pathogenesis.
To examine the evolution of FM diagnostic criteria.
To focus on pharmacologic management strategies for FM.

Main Methods:

Discussion of theoretical pathogenesis of FM.
Examination of diagnostic criteria evolution, moving from tender point exams to simpler criteria.
Review of pharmacologic agents for FM, including FDA-approved and non-approved drugs.

Main Results:

Non-pharmacologic therapies are effective but this review emphasizes pharmacologic options.
Discussion of individual drug profiles, patient response, and tolerability.
Presentation of a clinical algorithm for stepwise management of FM symptoms.

Conclusions:

Pharmacologic management is a key component of FM treatment.
Understanding drug profiles and patient factors is crucial for effective therapy.
A structured approach, like a clinical algorithm, aids in managing FM pain and associated symptoms.